Rationale for Targeting Multiple Lipid Pathways for Optimal Cardiovascular Risk Reduction

This publication has 13 references indexed in Scilit:

• Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia
  The American Journal of Cardiology, 2004
• Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction
  American Heart Journal, 2004
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
  Circulation, 2004
• Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
  New England Journal of Medicine, 2004
• Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia
  Circulation, 2003
• Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
  The Lancet, 2003
• Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
  JAMA, 2002
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
  Published by Elsevier ,2002
• Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively
  Atherosclerosis, 2001
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  JAMA, 2001